Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008
Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008: Cognition in Participants With Pyruvate Kinase Deficiency
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Agios Medical Affairs
- Phone Number: 833-228-8474
- Email: medinfo@agios.com
Study Locations
-
-
-
Milan, Italy, 20122
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
-
-
-
-
Utrecht, Netherlands, 3508 GA
- Universitair Medisch Centrum Utrecht
-
-
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participant must be ≥18 years of age;
- Participant must be enrolled in Study AG348-C-008.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
PK Deficiency Diagnosed Participants
Participants will receive online user access to the CBB.
Participants will complete 2 CBB assessments on Study Day 0 and Study Day 90.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change Over Time in Cogstate Brief Battery (CBB) Scores
Time Frame: Day 0, Day 90
|
CBB is a series of brief computerized assessments used to evaluate 4 major cognitive domains: psychomotor speed, attention/vigilance, visual learning, and working memory.
If the CBB score falls between -10 to +10, it is considered normal.
In Cogstate scoring 0 could be considered as performing in the average range, a negative score means below-average performance, and a positive score means above-average performance.
A positive change in scores indicates slightly better performance.
|
Day 0, Day 90
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CBB Scores of Participants as Compared to the Scores of Age-Matched Controls
Time Frame: Day 0, Day 90
|
CBB is a series of brief computerized assessments used to evaluate 4 major cognitive domains: psychomotor speed, attention/vigilance, visual learning, and working memory.
An age-standardized score of ≤-1 on a test will be defined as abnormal.
Cognitive impairment on the day of testing will be defined as ≥2 tests with abnormal performance.
|
Day 0, Day 90
|
|
Percentage of Participants With Blood Transfusions Affecting Cognition, as Assessed by the Investigator
Time Frame: Day 90
|
Day 90
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Medical Affairs, Agios Pharmaceuticals, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AG348-C-016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.